| Literature DB >> 36135275 |
Leshasha T Mashabela1, Mahlako M Maboa1, Ntombi F Miya1, Taiwo O Ajayi1, Rumbidzai S Chasara1, Marnus Milne1, Shoeshoe Mokhele1, Patrick H Demana1, Bwalya A Witika1, Xavier Siwe-Noundou1, Madan S Poka1.
Abstract
Gels are attractive candidates for drug delivery because they are easily producible while offering sustained and/or controlled drug release through various mechanisms by releasing the therapeutic agent at the site of action or absorption. Gels can be classified based on various characteristics including the nature of solvents used during preparation and the method of cross-linking. The development of novel gel systems for local or systemic drug delivery in a sustained, controlled, and targetable manner has been at the epitome of recent advances in drug delivery systems. Cross-linked gels can be modified by altering their polymer composition and content for pharmaceutical and biomedical applications. These modifications have resulted in the development of stimuli-responsive and functionalized dosage forms that offer many advantages for effective dosing of drugs for Central Nervous System (CNS) conditions. In this review, the literature concerning recent advances in cross-linked gels for drug delivery to the CNS are explored. Injectable and non-injectable formulations intended for the treatment of diseases of the CNS together with the impact of recent advances in cross-linked gels on studies involving CNS drug delivery are discussed.Entities:
Keywords: central nervous system; cross-linked gels; injectable cross-linked gels; non-injectable cross-linked gels; spatial drug delivery
Year: 2022 PMID: 36135275 PMCID: PMC9498590 DOI: 10.3390/gels8090563
Source DB: PubMed Journal: Gels ISSN: 2310-2861
Figure 1The blood-brain barrier and drug transporters in the capillary endothelial cells. (Blue arrows: Flow of molecules through influx transporters into the brain parenchyma from the blood vessel; Red arrows: Outward flow of molecules through efflux transporters from the brain parenchyma to the blood vessel) [Adapted from [17] in terms of the Creative Commons Attribution License (CC BY 3.0)].
Figure 2Classifications of cross-linked gels based on the nature of solvents.
Summary of cross-linked gels and applications.
| Class of Cross-Linked Gel | Advantages | Disadvantages | Applications | Ref |
|---|---|---|---|---|
|
| Thixotropic | Allergic reactions | Topical emulgel of mefenamic acid. | [ |
|
| Ease of preparation | Lack of biocompatibility formulations. | Intraocular flunarizine hydrochloride-loaded organogel | [ |
|
| Capable of retaining a high amount of water | It may be difficult to handle | Chemically cross-linked by glutaraldehyde for biomedical applications. | [ |
|
| High porosity | Low mechanical strength | Incorporation of niacin/nicotinic acid and ibuprofen in an aerogel | [ |
|
| Substantial pore size and porosity | Insufficient retention at injection site. | Thermoresponsive cryogels containing oligoehylene glycol | [ |
Figure 3Chemical structures and molecular weights (MW) of naturally derived polymers used in the manufacture of cross-linked gels.
Figure 4Chemical structures and molecular weights (MW) of various synthetic polymers used to manufacture cross-linked gels.
Figure 5Chemical structures and molecular weights (MW) of various natural crosslinkers used to manufacture cross-linked gels.
Figure 6Chemical structures and molecular weights (MW) of various synthetic crosslinkers used to manufacture cross-linked gels.
A summary of natural polymers, advantages, disadvantages, crosslinkers cross-linking agents or factors used and their effect.
| Polymer | Advantages | Disadvantages | Cross-Linking Agent or Factor | Effect | Ref |
|---|---|---|---|---|---|
|
| Antioxidant, Antifungal, Anti-inflammatory, Antibacterial | Relatively poor mechanical and barrier properties | Vanillin | Improves the balance of chitosan between affinity and insolubility in oil due to the hydrophobic methoxyphenyl group in the vanillin aromatic ring. | [ |
|
| Non-immunogenic | Thermosensitive | 2-chloro-1-methylpyridinium iodide (CMPI) | Activation of carboxylic acid sodium salt under heterogeneous reaction with high water uptake ability, reasonable biodegradability, and excellent cytocompatibility | [ |
|
| Non-toxic | Weak mechanical strength | Calcium ions | Alginate hydrogel changed weight by 10% in pure water and 90% in an isotonic solution | [ |
|
| High antigenicity | Ethical and cultural issues | Polypropyleneimine-octa-amine dendrimers | Supports adhesion and proliferation of human corneal epithelial cells without encouraging cellular toxicity | [ |
|
| Pure | Insoluble in most solvents | Citric acid | Formation of carboxylic bridges between cellulose fibril chains, thus preventing cellulose condensation during drying | [ |
|
| Non-immunogenic | Usefulness degraded by hyaluronidase | Faster degradation rate and smoother surfaces, lower cytotoxicity for corneal endothelial cells, and minimal inflammatory cell infiltration or foreign body reaction after implantation | [ | |
|
| Abundant and simple | Risk of infection transmission | Transglutaminase 2 (TG2) | Enhances proinflammatory activity to surface adhered fibrinogen | [ |
A summary of synthetic polymers, advantages, disadvantages, cross-linking agents or factors used and their effect.
| Polymer | Advantages | Disadvantages | Cross-Linking Agent or Factor | Effect | Ref |
|---|---|---|---|---|---|
|
| Amphiphilic | Low cell adhesion | Glutaraldehyde | Improved water flux and porosity | [ |
|
| Good thermal stability | Does not support cell proliferation and adhesion | Citric acid | Uniformly distributed membrane roughness, homogeneous films, enhanced adhesion, and strength properties with good stability. | [ |
|
| Low cytotoxicity | Weak mechanical properties | Improved drug, vaccine, and peptides encapsulation | [ | |
|
| Hydrophilic | Low mechanical strength | Glutaraldehyde | Improved mechanical properties due to covalent bonds formed using acidic catalysis. Improved tensile strength and elastic modulus. | [ |
|
| Hydrophilic | Thermal instability | The surface morphology of silicon wafers became thick, rough and thermo-responsive | [ | |
|
| Amphiphilic | Thermosensitive | Improved hydrophilic properties for the solubility of poorly soluble | [ |
Figure 7The various mechanisms of cross-linking that result in gelation [Obtained and reproduced without any changes from [87] and The Royal Society of Chemistry in accordance with Creative Commons Attribution License (CC BY)].
Figure 8Schematic of the composition of nanocomposite cross-linked gels with a hydrogel dispersion matrix and drug-loaded nanoparticles. [Obtained and re-produced without any changes from [172] and Nanomaterials MDPI in accordance with Creative Commons Attribution License (CC BY 4.0)].
Figure 9Schematic of drug release from nanogels in response to various stimuli [Obtained and reproduced without any changes from [183] and Gels MDPI in accordance with Creative Commons Attribution License (CC BY 4.0)].
Figure 10Pictorial illustration of the in-situ gel formation following the administration of drug loaded cross-linked gel for CNS conditions. Key: IN = Intranasal injection; IC = Intracranial; SC = Subcutaneous Injection, IV = Intravenous and IS = Intraspinal.
Summary of injectable cross-linked gels in CNS disorders.
| ROA | Polymer | Crosslinker | API | Disease | In-Vivo/In-Vitro Model | In-Vivo/In-Vitro Findings | Ref |
|---|---|---|---|---|---|---|---|
|
| PEG and PEI | Carbonyldiimidazole | Oligonucleotides | Neurodegenerative disorders | Mice | Better brain targeting with a 15-fold increase in accumulation of the drug in the brain and a 2-fold decrease in liver and spleen accumulation | [ |
|
| Polyglycerols | Disulfide | MicroRNA therapeutics | Glioblastoma Multiforme | Mice | Significantly inhibited tumor growth. | [ |
|
| Phosphorylcholine | Azobenzene-contained crosslinker | Doxorubicin | Glioblastoma | Mice | Favorable biocompatibility and long-circulating property in blood | [ |
|
| Poly( | carbodiimide hydrochloride and | Lactoferrin | Glioma | Rats | Highly sensitive and specific MR/fluorescence imaging | [ |
|
| Poly (propylene sulfide) 120 | Triglycerol monostearate | Curcumin | TBI | Mice | Enhanced brain drug accumulation resulting in improved regeneration and recovery of neurons | [ |
|
| Alginate | Calcium D-gluconate monohydrate | Paclitaxel (PTX) and Minocycline hydrochloride (MH) | Spinal cord injury (SCI) | Wistar rats | Increased neuronal regeneration after 28 days. | [ |
|
| PNIPAAm | poly (amidoamine) | Activin B | PD | Male C57BL/6J mice | Prolonged release of activin B of around 5 weeks | [ |
|
| Sodium | Calcium carbonate (CaCO3) | Human umbilical cord mesenchymal stem cells (hUC-MSCs) | Traumatic brain injury and stem cell tissue engineering | Sprague Dawley Rats | Enhanced regeneration of endogenous nerve cells. | [ |
|
| Hyaluronic acid | - | Donepezil | AD | Rats | Increased drug T1/2, reduced Cmax value, and sustained drug release over 7 days | [ |
|
| PEG and Polyethyleneimine (PEI) | 1,1′-carbonyldiimidazole | Zidovudine (AZT) | HIV-1 | Mice | Low neurotoxicity and improved antiviral suppression | [ |
|
| Poly(ethylene glycol)-b-poly(methacrylic acid) deblock copolymer | 1,2-ethylenedia-mine, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride | Cisplatin | Intracranial gliomas | Wistar rats | Enhanced inhibition of tumor growth and increased the life span of the animals | [ |
|
| 2-Dimethylamino ethyl methacrylate | Phenytoin sodium | Epilepsy | Male Sprague-Dawley rats | Higher distribution in the central nervous system | [ | |
|
| Pluronics® 407 (P 407), Pluronics® 188 (P 188) | - | Genipin | Depression | Male ICR mice | High drug release rate and improved antidepressant-like activities | [ |
|
| PVA | Carbodiimide | Doxorubicin | Integrin overexpressed human glioblastoma | Nude mice | Improved tumor targeting, tumor growth inhibition, and reduced side effects | [ |
|
| Chitosan | Polyanionic pentasodium triphosphate | Methotrexate | Brain tumor | Sprague Dawley Rats | Up to a 10-fold increase in brain concentrations of methotrexate compared to free drug. | [ |
Key: ROA = Route of Administration; IN = Intranasal injection; IT = Intratumoral; IC = Intracranial; IP = intraperitoneal, SC = Subcutaneous Injection, IV = Intravenous and IS = Intraspinal.
Summary of non-injectable cross-linked gels in CNS disorder.
| ROA | Polymer Used | Cross-Linking Agent/Factor Used | API/Agent Delivered | Human Disease | In-Vivo/In-Vitro Model | In-Vivo/In-Vitro Findings | Ref |
|---|---|---|---|---|---|---|---|
|
| Gellan gum | Heat | Sumatriptan succinate | Headaches | Sprague-Dawley rats | Improved brain targeting and bioavailability | [ |
|
| PF-127 | Heat | Tacrine | AD | Rats | Increased nasal residence time, improved bioavailability, and enhanced brain uptake | [ |
|
| PF-127 and PF-68 | Heat | Clozapine | Schizophrenia | Dialysis bag technique | Enhanced in-vitro drug release | [ |
|
| Pectin and poly(ethylene glycol)-block-polylactic acid (PEG-b-PLA) | Ca2+ | Olaparib | Brain tumor | Mice | High drug loading, improved in-vitro stability, and drug release over prolonged periods | [ |
|
| Poly(N-vinyl pyrrolidone)-co-acrylic acid | 1-ethyl-3-[3- dimethylaminopropyl] carbodiimide hydrochloride | Insulin | AD | Male C57BL/6J (B6) mice | Non-immunogenic response of the nasal mucosa. | [ |
|
| Sodium Alginate | Aqueous solvent | Pregabalin | Epilepsy | Dialysis membrane | Faster drug release, biodegradable, biocompatible, non-toxic, non-irritant, and no reaction on the skin were observed. | [ |
|
| Carbopol 934 and Pluronics® 407 | Potassium persulfate | Resveratrol | Brain tumors | Wistar albino rats | Good drug release properties. Safe and tolerable to the nasal mucosa | [ |
|
| Chitosan | Glutaraldehyde | Liposomal donepezil HCl | AD | New Zealand white rabbits | Significant increase in blood concentration and brain content of the API, compared to the oral tablets | [ |
Key: ROA = Route of Administration; IN = Intranasal and TC = Transcranial.